Fernandez E.L.,Comision de Monitorizacion de Farmacos y Toxicologia Clinica |
Pares L.,Comision de Monitorizacion de Farmacos y Toxicologia Clinica |
Pares L.,Hospital Universitario Doce Of Octubre |
Ajuria I.,Comision de Monitorizacion de Farmacos y Toxicologia Clinica |
And 13 more authors.
Clinical Chemistry and Laboratory Medicine | Year: 2010
Therapeutic drug monitoring (TDM) is a multidisciplinary activity. Because laboratory reports are part of the patient's chart, some clinical information is required. In order to guarantee quality and safety, an increasing number of TDM departments have implemented a quality management system. The aim of the present article is to review the three phases of TDM: the pre-analytical, analytical and post-analytical phases. In the pre-analytical phase, it is necessary to acquire a valid specimen collected at the specific time window. Analytical methods should be validated, assessing possible interfering substances. The objective of the post-analytical phase is the final report, which should include correct interpretation, as well as possible advice. Appropriate pharmacokinetic interpretation avoids unnecessary costs and leads to clinical benefits. © 2010 by Walter de Gruyter Berlin New York. Source